Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease a systematic review and meta-analysis

JAMA

Volumn 305, Issue 11, 2011, Pages 1119-1127

  Palmer, Suetonia C ^a,b   Hayen, Andrew ^c   Macaskill, Petra ^c   Pellegrini, Fabio ^d,e   Craig, Jonathan C ^c,f   Elder, Grahame J ^g   Strippoli, Giovanni F M ^c,d,f,h  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Mario Negri Sud Consortium ^*  (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f University of Sydney   (Australia)

^g WESTMEAD HOSPITAL   (Australia)

^h Medical Scientific Office   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHORUS;

CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DISEASE ASSOCIATION; HUMAN; META ANALYSIS (TOPIC); MORTALITY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW;

EID: 79952604526     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.308     Document Type: Review

References (79)

1. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Guidelines for anemia of chronic kidney disease: 2000. http://www.kidney.org/ professionals/kdoqi/guidelines-updates/doqiupan-ii.html. Accessed February 6, 2011.
2. Revised European Best Practice Guidelines for the Management of Anaemia in Patients With Chronic Renal Failure: section II: targets for anaemia treatment. Nephrol Dial Transplant. 2004;19(suppl 2):ii6-ii15.
3. Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity. Nephrol Dial Transplant. 1998;13(7):1642-1644. (Pubitemid 28306788)
4. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10(3):610-619. (Pubitemid 29117643)
5. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339(9):584-590. (Pubitemid 28385655)
6. Singh AK, Szczech L, Tang KL, et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098. (Pubitemid 44749317)
7. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019- 2032.
8. Moe SM, Drüeke T, Lameire N, et al. Chronic kidney disease-mineral-bone disorder. Adv Chronic Kidney Dis. 2007;14(1):3-12.
9. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4)(Suppl 3):S1-S201.
10. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney diseasemineral and bone disorder (CKD-MBD). Kidney Int. 2009;76(suppl 113):S1-S130.
11. Navaneethan SD, Palmer SC, Craig JC, et al. Benefits and harms of phosphate binders in CKD. Am J Kidney Dis. 2009;54(4):619-637.
12. Palmer SC, McGregor DO, Macaskill P, et al. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med. 2007;147(12):840-853. (Pubitemid 351664426)
13. Strippoli GFM, Palmer SC, Tong A, et al. Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis. 2006;47(5):715-726.
14. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 2007;72(9):1130-1137. (Pubitemid 47609037)
15. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions. Ann Intern Med. 2009;151(4):W65-94.
16. Berlin JA, Longnecker MP, Greenland S. Meta-analysis of epidemiologic dose-response data. Epidemiology. 1993;4(3):218-228. (Pubitemid 23159532)
17. Avram MM, Sreedhara R, Fein P, et al. Survival on hemodialysis and peritoneal dialysis over 12 years with emphasis on nutritional parameters. Am J Kidney Dis. 2001;37(1)(suppl 2):S77-S80. (Pubitemid 32048029)
18. Noordzij M, Korevaar JC, Boeschoten EW, et al. The kidney disease outcomes quality initiative (K/DOQI) guideline for bone metabolism and disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis. 2005;46(5):925-932. (Pubitemid 41505468)
19. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006;144(6):427-437. (Pubitemid 46768164)
20. Hartemink N, Boshuizen HC, Nagelkerke NJ, et al. Combining risk estimates from observational studies with different exposure cutpoints. Am J Epidemiol. 2006;163(11):1042-1052.
21. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients. Am J Kidney Dis. 1998;31(4):607-617.
22. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208-2218. (Pubitemid 39031360)
23. Ganesh SK, Stack AG, Levin NW, et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001;12(10):2131-2138. (Pubitemid 32880350)
24. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771-780. (Pubitemid 44215354)
25. Kimata N, Albert JM, Akiba T, et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients [published correction appears in Hemodial Int. 2009;13(1):91]. Hemodial Int. 2007;11(3):340-348. (Pubitemid 46958589)
26. Lacson E Jr, Wang W, Hakim RM, et al. Associates of mortality and hospitalization in hemodialysis. Am J Kidney Dis. 2009;53(1):79-90.
27. Port FK, Pisoni RL, Bragg-Gresham JL, et al. DOPPS estimates of patient life years attributable to modifiable hemodialysis practices in the United States. Blood Purif. 2004;22(1):175-180. (Pubitemid 38142303)
28. Rubel JR, Milford EL. The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemodialysis population. Am J Kidney Dis. 2003;41(2):411-421. (Pubitemid 36152461)
29. Saran R, Bragg-Gresham JL, Rayner HC, et al. Non-adherence in hemodialysis. Kidney Int. 2003;64(1):254-262.
30. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients. JAmSoc Nephrol. 2005;16(6):1788-1793. (Pubitemid 41716485)
31. Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH.AmJ Kidney Dis. 2008;52(3):519-530.
32. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism. Kidney Int. 2005;67(3):1179-1187.
33. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis. 2000;36(6):1115-1121.
34. Drechsler C, Krane V, Grootendorst DC, et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrol Dial Transplant. 2009;24(10):3151-3157.
35. Dukkipati R, Kovesdy CP, Colman S, et al. Association of relatively low serum parathyroid hormone with malnutrition. J Ren Nutr. 2010;20(4):243-254.
36. Dussol B, Morand P, Martinat C, et al. Influence of parathyroidectomy on mortality in hemodialysis patients. Ren Fail. 2007;29(5):579-586.
37. Guh JY, Chen HC, Chuang HY, et al. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis. 2002;39(6):1245-1254.
38. Jassal SV, Douglas JF, Stout RW. Prognostic markers in older patients starting renal replacement therapy. Nephrol Dial Transplant. 1996;11(6):1052-1057. (Pubitemid 26182498)
39. Komaba H, Igaki N, Takashima M, et al. Calcium, phosphorus, cardiovascular events and allcause mortality in hemodialysis patients. Ther Apher Dial. 2008;12(1):42-48.
40. Marco MP, Craver L, Betriu A, et al. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int Suppl. 2003;(85):S111-S114. (Pubitemid 36608935)
41. Morrone LF, Mazzaferro S, Russo D, et al. Interaction between parathyroid hormone and the Charlson comorbidity index on survival of incident haemodialysis patients. Nephrol Dial Transplant. 2009;24(9):2859-2865.
42. Rodriguez-Benot A, Martin-Malo A, Alvarez-Lara MA, et al. Mild hyperphosphatemia and mortality in hemodialysis patients. Am J Kidney Dis. 2005;46(1):68-77. (Pubitemid 40848434)
43. Spiegel DM, Raggi P, Smits G, Block GA. Factors associated with mortality in patients new to haemodialysis. Nephrol Dial Transplant. 2007;22(12):3568- 3572. (Pubitemid 350212490)
44. Wald R, Sarnak MJ, Tighiouart H, et al. Disordered mineral metabolism in hemodialysis patients.Am J Kidney Dis. 2008;52(3):531-540.
45. Cueto-Manzano AM, Quintana-Piña E, Correa-Rotter R. Long-term CAPD survival and analysis of mortality risk factors. Perit Dial Int. 2001;21(2):148-153.
46. Dimkovic NB, Bargman J, Vas S, Oreopoulos DG. Normal or low initial PTH levels are not a predictor of morbidity/mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int. 2002;22(2):204-210. (Pubitemid 34546332)
47. Hakemi MS, Golbabaei M, Nassiri A, et al. Predictors of patient survival in continuous ambulatory peritoneal dialysis. Iran J Kidney Dis. 2010;4(1):44-49.
48. Foley RN, Parfrey PS, Harnett JD, et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol. 1996;16(5):386-393. (Pubitemid 26316938)
49. Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients. Kidney Int. 2006;70(2):351-357. (Pubitemid 44086585)
50. Osawa Y, Aoike I, Sakurabayashi T, et al. Serum calcium levels at first renal replacement therapy and patients survival. Clin Calcium. 2005;15(suppl 1):167-172.
51. Phelan PJ, O'Kelly P, Walshe JJ, et al. The importance of serum albumin and phosphorous as predictors of mortality in ESRD patients. Ren Fail. 2008;30(4):423-429. (Pubitemid 351868691)
52. Stevens LA, Djurdjev O, Cardew S, et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality. J Am Soc Nephrol. 2004;15(3):770-779.
53. Fellah H, Hammami MB, Feki M, et al. Predictors for cardiovascular morbidity and overall mortality in Tunisian ESRD patients. Clin Biochem. 2009;42(7-8):648-653.
54. Connolly GM, Cunningham R, McNamee PT, et al. Elevated serum phosphate predicts mortality in renal transplant recipients. Transplantation. 2009;87(7):1040-1044.
55. Egbuna OI, Taylor JG, Bushinsky DA, Zand MS. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant. 2007;21(4):558-566. (Pubitemid 47177046)
56. Krüger B, Schnitzbauer AA, Böger CA, et al. Pre-transplant calcium levels have no predictive value for delayed graft function, long-term graft function, cardiovascular events, or graft and patient survival in renal transplantation. Transplant Proc. 2006;38(3):697-700.
57. Schaeffner ES, Födinger M, Kramar R, et al. Prognostic associations of serum calcium, phosphate and calcium phosphate concentration product with outcomes in kidney transplant recipients. Transpl Int. 2007;20(3):247-255.
58. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005;16(2):520-528. (Pubitemid 41725150)
59. Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008;73(11):1296-1302. (Pubitemid 351693159)
60. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease. Clin Nephrol. 2010;73(4):268-275.
61. Menon V, Greene T, Pereira AA, et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis. 2005;46(3):455-463. (Pubitemid 41208181)
62. Roodnat JI, van Gurp EA, Mulder PG, et al. High pretransplant parathyroid hormone levels increase the risk for graft failure after renal transplantation. Transplantation. 2006;82(3):362-367. (Pubitemid 44223035)
63. Smith DH, Johnson ES, Thorp ML, et al. Outcomes predicted by phosphorous in chronic kidney disease. Nephrol Dial Transplant. 2010;25(1):166-174.
64. Smith DH, Johnson ES, Thorp ML, et al. Hyperparathyroidism in chronic kidney disease. J Bone Miner Metab. 2009;27(3):287-294.
65. Voormolen N, Noordzij M, Grootendorst DC, et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007;22(10):2909-2916. (Pubitemid 350093423)
66. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women. JAMA. 2002;288(3):321-333.
67. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.NEngl J Med. 1989;321(6):406-412.
68. Lebner AC, Beard KM, Soroka SD, et al. Interprovincial differences in the achievement of K/DOQI targets of mineral metabolism in Canada. Nephrol Dial Transplant. 2011;26(1):156-163.
69. Blayney MJ, Tentori F. Trends and consequences of mineral bone disorder in haemodialysis patients. J Ren Care. 2009;35(suppl 1):7-13.
70. Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol. 2009;4(6):1089-1096.
71. Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol. 2009;20(2):388-396.
72. St Peter WL, Li S, Liu J, et al. Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis. Pharmacotherapy. 2009;29(2):154-164.
73. Sugiura S, Inaguma D, Kitagawa A, et al. Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clin Exp Nephrol. 2010;14(1):43-50.
74. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival. J Am Soc Nephrol. 2005;16(4):1115-1125. (Pubitemid 41710323)
75. Bodyak N, Ayus JC, Achinger S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A. 2007;104(43):16810-16815. (Pubitemid 350210947)
76. Block GA, Persky MS, Ketteler M, et al. A randomized double-blind pilot study of serum phosphorus normalization in chronic kidney disease. Hemodial Int. 2009;13(3):360-362.
77. Kilkkinen A, Knekt P, Aro A, et al. Vitamin D status and the risk of cardiovascular disease death. Am J Epidemiol. 2009;170(8):1032-1039.
78. Mehrotra R, Kermah DA, Salusky IB, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009;76(9):977-983.
79. Tonelli M, Curhan G, Pfeffer M, et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation. 2009;120(18):1784-1792.